About Bioline  All Journals  Testimonials  Membership  News

Memórias do Instituto Oswaldo Cruz
Fundação Oswaldo Cruz, Fiocruz
ISSN: 1678-8060
EISSN: 1678-8060
Vol. 100, No. 6, 2005, pp. 671-677
Bioline Code: oc05142
Full paper language: English
Document type: Research Article
Document available free of charge

Memórias do Instituto Oswaldo Cruz, Vol. 100, No. 6, 2005, pp. 671-677

 en Antimicrobial susceptibility patterns of unusual nonfermentative gram-negative bacilli isolated from Latin America: report from the SENTRY Antimicrobial Surveillance Program (1997-2002)
Ana C Gales; Ronald N Jones; Soraya S Andrade & Helio S Sader


The antimicrobial susceptibility of 176 unusual non-fermentative gram-negative bacilli (NF-GNB) collected from Latin America region through the SENTRY Program between 1997 and 2002 was evaluated by broth microdilution according to the National Committee for Clinical Laboratory Standards (NCCLS) recommendations. Nearly 74% of the NF-BGN belonged to the following genera/species: Burkholderia spp. (83), Achromobacter spp. (25), Ralstonia pickettii check for this species in other resources (16), Alcaligenes spp. (12), and Cryseobacterium spp. (12). Generally, trimethoprim/sulfamethoxazole (MIC50, ≤ 0.5 μg/ml) was the most potent drug followed by levofloxacin (MIC50, 0.5 μg/ml), and gatifloxacin (MIC50, 1 μg/ml). The highest susceptibility rates were observed for levofloxacin (78.3%), gatifloxacin (75.6%), and meropenem (72.6%). Ceftazidime (MIC50, 4 μg/ml; 83.1% susceptible) was the most active β-lactam against B. cepacia. Against Achromobacter spp. isolates, meropenem (MIC50, 0.25 μg/ml; 88% susceptible) was more active than imipenem (MIC50, 2 μg/ml). Cefepime (MIC50, 2 μg/ml; 81.3% susceptible), and imipenem (MIC50, 2 μg/ml; 81.3% susceptible) were more active than ceftazidime (MIC50, >16 μg/ml; 18.8% susceptible) and meropenem (MIC50, 8 μg/ml; 50% susceptible) against Ralstonia pickettii. Since selection of the most appropriate antimicrobial agents for testing and reporting has not been established by the NCCLS for many of NF-GNB species, results from large multicenter studies may help to guide the best empiric therapy.

antimicrobial susceptibility - nonfermentative gram-negative -Latin America - SENTRY

© Copyright 2005 - Instituto Oswaldo Cruz - Fiocruz.
Alternative site location:

Home Faq Resources Email Bioline
© Bioline International, 1989 - 2024, Site last up-dated on 01-Sep-2022.
Site created and maintained by the Reference Center on Environmental Information, CRIA, Brazil
System hosted by the Google Cloud Platform, GCP, Brazil